/
/
Real World Vs. Clinical Trial Multiple Myeloma Outcomes Can Differ
Real World Vs. Clinical Trial Multiple Myeloma Outcomes Can Differ image
Real World Vs. Clinical Trial Multiple Myeloma Outcomes Can Differ
Posted Aug 22, 2018

Survival outcomes in real-world practice may not mirror outcomes found in clinical trials for non-transplant patients with multiple myeloma, according to research published in the Annals of Hematology.

More modern treatments are helping multiple myeloma patients live longer, but myeloma still remains incurable for most patients. The research community assesses patient outcomes from data inside of clinical trials, but this type of data may not transfer to how patients respond when outside of a clinical trial. 

A group of German researchers led by Norbert Marschner, MD in Freiburg, Germany conducted a study based on  to assess trial eligibility, sequential treatment, and survival of non-transplant patients with multiple myeloma treated in routine care.

The study from the German Tumor Registry Lymphatic Neoplasms enrolled 3795 patients with blood cancers after first- or second-line therapy. A total of 285 non-transplant patients received treatment for multiple myeloma.

Thirty percent of patients with other health conditions like heart/renal failure, liver/renal diseases, polyneuropathy, and HIV-positive status were excluded from the study.

Researchers reported that regardless of the intervention, the median progression-free survival (PFS) and overall survival (OS) were significantly higher among patients who were trial-eligible (27.3 months) compared to patients who did not qualify for the trial (16.2 months).

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811